Editorial comment on 'A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy' by Schmitt et al

Eur J Cancer. 2002 Nov;38(17):2207-9. doi: 10.1016/s0959-8049(02)00476-8.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Animals
  • Apoptosis / genetics
  • Cyclin-Dependent Kinase Inhibitor p16 / genetics*
  • DNA Damage
  • Drug Resistance, Neoplasm / genetics
  • Genes, p53 / genetics*
  • Lymphoma, B-Cell / genetics*
  • Mice
  • Mice, Transgenic
  • Neoplasm Transplantation
  • Transfection
  • Treatment Outcome

Substances

  • Cyclin-Dependent Kinase Inhibitor p16